Blockade of tumour necrosis factor-α in experimental autoimmune encephalomyelitis reveals differential effects on the antigen-specific immune response and central nervous system histopathology

Clinical and Experimental Immunology

Volumn 175, Issue 1, 2014, Pages 41-48

  Batoulis, H ^a   Recks, M S ^a   Holland, F O ^a   Thomalla, F ^a   Williams, R O ^c   Kuerten, S ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

EAE MS; Inflammation; Monocytes macrophages; Neuroimmunology; T cells

Indexed keywords

ADALIMUMAB; ETANERCEPT; GAMMA INTERFERON; INTERLEUKIN 17; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE SEVERITY; HISTOPATHOLOGY; IMMUNIZATION; IMMUNOMODULATION; MOUSE; NERVE FIBER; NONHUMAN; PRIORITY JOURNAL; SPINAL CORD; SPLEEN; TH1 CELL; TH17 CELL;

EAE/MS; INFLAMMATION; MONOCYTES/MACROPHAGES; NEUROIMMUNOLOGY; T CELLS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; MICE; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; PEPTIDE FRAGMENTS; SPLEEN; TH1 CELLS; TH17 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84888856434     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12209     Document Type: Article

References (31)

1. Dopp JM, Sarafian TA, Spinella FM, Kahn MA, Shau H, de Vellis J. Expression of the p75 TNF receptor is linked to TNF-induced NFkappaB translocation and oxyradical neutralization in glial cells. Neurochem Res 2002; 27:1535-1542.
2. Cheng X, Yang L, He P, Li R, Shen Y. Differential activation of tumor necrosis factor receptors distinguishes between brains from Alzheimer's disease and non-demented patients. J Alzheimers Dis 2010; 19:621-630.
3. Faustman D, Davis M. TNF receptor 2 pathway: drug target for autoimmune diseases. Nat Rev Drug Discov 2010; 9:482-493.
4. Kollias G, Kontoyiannis D. Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments. Cytokine Growth Factor Rev 2002; 13:315-321.
5. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001; 19:163-196.
6. Martínez F, Nos P, Benlloch S, Ponce J. Hidradenitis suppurativa and Crohn's disease: response to treatment with infliximab. Inflamm Bowel Dis 2001; 7:323-326.
7. Heiberg MS, Koldingsnes W, Mikkelsen K etal. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum 2008; 59:234-240.
8. Reich K, Nestle FO, Papp K etal. EXPRESS study investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366:1367-1374.
9. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005; 128:862-869.
10. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999; 53:457-465.
11. Kodama S, Davis M, Faustman DL. The therapeutic potential of tumor necrosis factor for autoimmune disease: a mechanistically based hypothesis. Cell Mol Life Sci 2005; 62:1850-1862.
12. Mix E, Meyer-Rienecker H, Hartung HP, Zettl UK. Animal models of multiple sclerosis-potentials and limitations. Prog Neurobiol 2010; 92:386-404.
13. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992; 89:9784-9788.
14. Notley CA, Inglis JJ, Alzabin S, McCann FE, McNamee KE, Williams RO. Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. J Exp Med 2008; 205:2491-2497.
15. Baker D, Butler D, Scallon BJ, O'Neill JK, Turk JL, Feldmann M. Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur J Immunol 1994; 24:2040-2048.
16. Taoufik E, Tseveleki V, Chu SY etal. Transmembrane tumour necrosis factor is neuroprotective and regulates experimental autoimmune encephalomyelitis via neuronal nuclear factor-kappaB. Brain 2011; 134:2722-2735.
17. Kruglov AA, Lampropoulou V, Fillatreau S, Nedospasov SA. Pathogenic and protective functions of TNF in neuroinflammation are defined by its expression in T lymphocytes and myeloid cells. J Immunol 2011; 187:5660-5670.
18. Liu J, Marino MW, Wong G etal. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat Med 1998; 4:78-83.
19. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338:278-285.
20. Rottlaender A, Villwock H, Addicks K, Kuerten S. Neuroprotective role of fibroblast growth factor-2 in experimental autoimmune encephalomyelitis. Immunology 2011; 133:370-378.
21. Chen X, Oppenheim JJ. Contrasting effects of TNF and anti-TNF on the activation of effector T cells and regulatory T cells in autoimmunity. FEBS Lett 2011; 585:3611-3618.
22. Ma HL, Napierata L, Stedman N etal. Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells. Arthritis Rheum 2010; 62:430-440.
23. Kleijwegt FS, Laban S, Duinkerken G etal. Critical role for TNF in the induction of human antigen-specific regulatory T cells by tolerogenic dendritic cells. J Immunol 2010; 185:1412-1418.
24. Ablamunits V, Bisikirska B, Herold KC. Acquisition of regulatory function by human CD8(+) T cells treated with anti-CD3 antibody requires TNF. Eur J Immunol 2010; 40:2891-2901.
25. Housley WJ, Adams CO, Nichols FC etal. Natural but not inducible regulatory T cells require TNF-alpha signaling for in vivo function. J Immunol 2011; 186:6779-6787.
26. Eliçabe RJ, Cargnelutti E, Serer MI etal. Lack of TNFR p55 results in heightened expression of IFN-γ and IL-17 during the development of reactive arthritis. J Immunol 2010; 185:4485-4495.
27. O'Connor W Jr, Kamanaka M, Booth CJ etal. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol 2009; 10:603-609.
28. Gunnlaugsdottir B, Skaftadottir I, Ludviksson BR. Naive human T-cells become non-responsive towards anti-TNFalpha (infliximab) treatment in vitro if co-stimulated through CD28. Scand J Immunol 2008; 68:624-634.
29. Mc Guire C, Volckaert T, Wolke U etal. Oligodendrocyte-specific FADD deletion protects mice from autoimmune-mediated demyelination. J Immunol 2010; 185:7646-7653.
30. Mc Guire C, Beyaert R, van Loo G. Death receptor signalling in central nervous system inflammation and demyelination. Trends Neurosci 2011; 34:619-628.
31. Sheng WS, Hu S, Ni HT, Rowen TN, Lokensgard JR, Peterson PK. TNF-alpha-induced chemokine production and apoptosis in human neural precursor cells. J Leukoc Biol 2005; 78:1233-1241.